Noxopharm in trading halt

Posted 15 November 2021 PM

Sydney-based Noxopharm has called a trading halt on the ASX after receiving one of the largest grants ever handed out to a biotech for a single drug program from the Australian Government's Medical Research Future Fund (MRFF).

This morning, Noxopharm was awarded $8.79 million through the MRFF's Rapid Applied Research Translational initiative to cover the cost of a clinical trial, part of its Chemotherapy Enhancement Program (CEP), investigating the combination of Veyonda and standard of care chemotherapy drug, doxorubicin, in patients with soft tissue sarcoma (STS).

To see the whole article, please login